MGB Biopharma has announced an update on progress in its Phase IIa clinical study assessing the safety, tolerability and efficacy of incremental doses of MGB-BP-3 in patients with clostridium difficile-associated diarrhoea (CDAD).
GLASGOW, Scotland, Oct. 10, 2019 /PRNewswire/ -- MGB Biopharma, a biopharmaceutical company developing a novel class of anti-infectives to address the major global problem of antibiotic resistance, today announces an update on progress in its Phase IIa clinical study.